Linked Life Data

18228212

Source:http://linkedlifedata.com/resource/pubmed/id/18228212

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-29
pubmed:abstractText
To date, Hodgkin's lymphoma (HL) patients have achieved long-term survival of more than 80%. Unfortunately, longer follow-up has shown serious adverse effects of the treatments used. For this reason, therapeutic strategies are becoming more tailored to the individual patient s prognosis. Pre-treatment risk factors for early-stage and advanced-stage HL are well known indicators of prognosis. Recently, early interim (18)F-FDG PET has been shown as a strong and independent predictor of progression-free survival in HL. Our aim was to assess response to therapy by repeating (18)F-FDG-PET/CT after four and six chemotherapy cycles.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1506-9680
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
87-90
pubmed:dateRevised
2011-10-13
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
pubmed:affiliation
Department of Oncology and Onco-haematology, S. Maria della Misericordia Rovigo Hospital, Rovigo, Italy.
pubmed:publicationType
Journal Article, Clinical Trial